Keyphrases
Hematopoietic Stem Cells
100%
Hematopoietic Stem Cell Mobilization
100%
CXCR4 Inhibitor
100%
Motixafortide
100%
CD34+ Stem Cells
28%
Hematopoietic Stem Cell Transplantation
21%
Granulocyte Colony-stimulating Factor (G-CSF)
21%
Cell-based
14%
CD34+ Cells
14%
Gene-edited
14%
Cell number
7%
Adverse Events
7%
Life-threatening
7%
Gene Therapy
7%
Gene Editing
7%
Chemotherapy
7%
Stem Cell Mobilization
7%
Patient Demographics
7%
Sickle Cell Disease
7%
Peripheral Blood
7%
Thrombotic Events
7%
Leukapheresis
7%
Bone Pain
7%
Plerixafor
7%
Mobilizing Agents
7%
Mobilization Regimen
7%
In Vivo Activity
7%
Immunophenotyping
7%
Mobilization Strategies
7%
Pre-clinical and Clinical Trials
7%
Recent Innovation
7%
Vaso-occlusive Events
7%
Single-cell RNA
7%
RNA Expression Profiling
7%
Splenic Rupture
7%
Pharmacology, Toxicology and Pharmaceutical Science
Granulocyte Colony Stimulating Factor
100%
Clinical Trial
33%
Adverse Event
33%
Chemotherapy
33%
Plerixafor
33%
Bone Pain
33%
Sickle Cell Anemia
33%
Spleen Rupture
33%
Medicine and Dentistry
Stem Cell Mobilization
100%
Hematopoietic Cell
100%
Hematopoietic Stem Cell Transplantation
15%
Granulocyte Colony Stimulating Factor
15%
Clinical Trial
5%
Adverse Event
5%
Gene Therapy
5%
Patient Population
5%
Plerixafor
5%
Bone Pain
5%
Patient with Sickle Cell Disease
5%
Leukapheresis
5%
Immunophenotyping
5%
Spleen Rupture
5%
Biochemistry, Genetics and Molecular Biology
CXCR4
100%
Hematopoietic Cell
100%
CD34
19%
Hematopoietic Stem Cell Transplantation
14%
Granulocyte Colony-Stimulating Factor
14%
Stem Cell
4%
Clinical Trial
4%
Gene Therapy
4%
Genome Editing
4%
RNA
4%
Immunophenotyping
4%
Leukapheresis
4%
Immunology and Microbiology
Hematopoietic Cell
100%
CXCR4
100%
CD34
19%
Hematopoietic Stem Cell Transplantation
14%
Granulocyte Colony-Stimulating Factor
14%
Stem Cell
4%
Sickle Cell
4%
Plerixafor
4%
Leukapheresis
4%
Gene Editing
4%